Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentr... by Wu, Yi-Long, Prof, Guarneri, Valentina, Prof, Voon, Pei Jye, MD, Lim, Boon Khaw, MRCP, Yang, Jin-Ji, Prof, Wislez, Marie, Prof, Huang, Cheng, Prof, Liam, Chong Kin, Prof, Mazieres, Julien, Prof, Tho, Lye Mun, PhD, Hayashi, Hidetoshi, Prof, Nhung, Nguyen Viet, PhD, Chia, Puey Ling, PhD, de Marinis, Filippo, Prof, Raskin, Jo, MD, Zhou, Qinghua, Prof, Finocchiaro, Giovanna, MD, Le, Anh Tuan, PhD, Wang, Jialei, Prof, Dooms, Christophe, PhD, Kato, Terufumi, PhD, Nadal, Ernest, PhD, Hin, How Soon, Prof, Smit, Egbert F, Prof, Wermke, Martin, Prof, Tan, Daniel, PhD, Morise, Masahiro, PhD, O'Brate, Aurora, PhD, Adrian, Svenja, MD, Pfeiffer, Boris M, MD, Stroh, Christopher, PhD, Juraeva, Dilafruz, PhD, Strotmann, Rainer, MD, Goteti, Kosalaram, MD, Berghoff, Karin, MD, Ellers-Lenz, Barbara, MSc, Karachaliou, Niki, MD, Le, Xiuning, MD, Kim, Tae Min, Prof

Get full text